Timothy Cloughesy, MD
Neurology · Los Angeles, CANPI 1154356053
Payments from drug & device makers
Across 893 payments — averaging $37,055 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$18.4M
- Servier Bioinnovation$6.7M
- AstraZeneca$2.2M
- Merck$2.1M
- Servier Pharmaceuticals LLC$1.5M
- Amgen$870K
- plus $1.4M from 19 others
Across 29 payments — averaging $726.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Servier Bioinnovation$8K
- Servier Affaires Medicales$7K
- Pfizer$3K
- Servier Pharmaceuticals LLC$1K
- Bristol Myers Squibb$886
- F. Hoffmann-la Roche AG$197
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 2 | $18,360,000 |
| Servier Bioinnovation | 399 | $6,680,580 |
| AstraZeneca | 8 | $2,196,736 |
| Merck | 18 | $2,113,382 |
| Servier Pharmaceuticals LLC | 51 | $1,493,344 |
| Amgen | 23 | $870,173 |
| Agios Pharmaceuticals, Inc. | 68 | $839,446 |
| Genentech, Inc. | 10 | $247,184 |
| Novartis | 10 | $86,746 |
| Beigene, Ltd. | 13 | $46,103 |
| Stemline Therapeutics Inc. | 10 | $39,467 |
| AbbVie | 8 | $24,061 |
| Bayer | 15 | $21,901 |
| Servier Affaires Medicales | 5 | $17,332 |
| GW Research Limited | 1 | $14,700 |
| F. Hoffmann-la Roche AG | 5 | $9,990 |
| Boehringer Ingelheim | 3 | $7,535 |
| Boehringer Ingelheim RCV GmbH & Co KG | 4 | $7,245 |
| Deciphera Pharmaceuticals Inc. | 233 | $6,513 |
| Jazz Pharmaceuticals Inc. | 1 | $3,296 |
| Novocure Inc. | 1 | $3,000 |
| Jubilant Therapeutics Inc | 1 | $750 |
| Exelixis Inc. | 2 | $690 |
| Celularity Inc. | 1 | $55 |
| Illumina, Inc. | 1 | $25 |
How this compares
$33,090,253 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$8.2M
- Jeffrey SaverLos Angeles$2.9M
- David PiccioniLos Angeles$2.9M
- David LiebeskindLos Angeles$2.7M
- Michele TagliatiLos Angeles$2.5M
- Jennifer HuiLos Angeles$2.4M
- Susan PerlmanLos Angeles$2.2M
- Jeffrey CummingsLos Angeles$2M
- Bryan SpannLos Angeles$1.8M
- Lilyana AmezcuaLos Angeles$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.